Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Ole Lederballe-Pedersen"'
Autor:
Ole Lederballe Pedersen
Publikováno v:
Acta Pharmacologica et Toxicologica. 49:1-32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1b6277408e7fafeb7e99b2cb48fda69
https://doi.org/10.1111/j.1600-0773.1981.tb03365.x
https://doi.org/10.1111/j.1600-0773.1981.tb03365.x
Publikováno v:
Acta Pharmacologica et Toxicologica. 45:249-256
In isolated human crural arteries and veins, digoxin induced slowly developing, long-lasting contractions. These contractions were not diminished by α-adrenoceptor blockade or by washing, but were abolished by the calcium antagonist nifedipine. In t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9ea9ae4d697388c156a619a954be8bd
https://doi.org/10.1111/j.1600-0773.1979.tb02390.x
https://doi.org/10.1111/j.1600-0773.1979.tb02390.x
Autor:
Hans Ibsen, Gareth Beevers, Giovanni de Simone, Per Omvik, Hans Wedel, Ulf de Faire, Kristian Wachtell, Richard B. Devereux, Björn Dahlöf, Suzanne Oparil, Markku S. Nieminen, Frej Fyhrquist, Sverre E. Kjeldsen, Lars H Lindholm, Ole Lederballe-Pedersen, Michael H. Olsen, Paulette A. Lyle
Publikováno v:
Journal of Hypertension. 27:567-574
Beta-blockers and angiotensin II receptor blockers have different effects on lipids.We examined lipid levels in the Losartan Intervention For Endpoint reduction in hypertension study and their impact on the primary composite endpoint of cardiovascula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fb83053a037231fac28f464538ae08f
https://doi.org/10.1097/hjh.0b013e32831daf96
https://doi.org/10.1097/hjh.0b013e32831daf96
Autor:
Suzanne Oparil, Sverre E. Kjeldsen, Frej Fyhrquist, Ole Lederballe-Pedersen, Gareth Beevers, Björn Dahlöf, Puneet Narayan, Lars H Lindholm, Hans Ibsen, Per Omvik, Hans Wedel, Markku S. Nieminen, Richard B. Devereux, Michael H. Olsen, Ulf de Faire, Kristian Wachtell
Publikováno v:
American Heart Journal. 157:177-184
The prognostic importance of hemoglobin is controversial. We investigated the prognostic importance of baseline and in-treatment hemoglobin in the LIFE study.Eight thousand one hundred ninety-four LIFE patients with hypertension and left ventricular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c6a2b5429602561ffd34ddb2e8911bf
https://doi.org/10.1016/j.ahj.2008.08.011
https://doi.org/10.1016/j.ahj.2008.08.011
Autor:
C.G. Calvo-Vargas, Michael A. Weber, Alberto Zanchetti, Gordon T. McInnes, Stevo Julius, Kostas C. Siamopoulos, Ole Lederballe Pedersen, Nicolaas J. Holwerda, Andrzej Cieśliński, Sverre E. Kjeldsen, Tsushung Hua, Faustinus P. Rudyatmoko, Öyvind Störset, Janna Kobalava, Jean-Paul Degaute, John H. Laragh, Francis Plat, Edouard Battegay
Publikováno v:
Journal of Hypertension. 24:2163-2168
Background In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial the primary outcome (cardiac morbidity and mortality) did not differ between valsartan and amlodipine-based treatment groups, although systolic blood pressure (SBP) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5fb690cea9a97bea5dd95a8aa824e3b
https://doi.org/10.1097/01.hjh.0000249692.96488.46
https://doi.org/10.1097/01.hjh.0000249692.96488.46
Autor:
Jonathan M. Edelman, Steven M. Snapinn, Ole Lederballe-Pedersen, Suzanne Oparil, Hans Ibsen, Björn Dahlöf, Stevo Julius, Frej Fyhrquist, Sverre E. Kjeldsen, Richard B. Devereux, Krister Kristianson, Andreas Moan, Lars H Lindholm, Ulf de Faire, Markku S. Nieminen, Per Omvik, Hans Wedel, Eigil Fossum
Publikováno v:
Journal of the American College of Cardiology. 46:770-775
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin : the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c6e2579d0234bd95e71976474e34298
https://doi.org/10.1016/j.jacc.2005.05.060
https://doi.org/10.1016/j.jacc.2005.05.060
Autor:
Gareth Beevers, Richard B. Devereux, Ulf de Faire, Sverre E. Kjeldsen, Darcy A. Hille, Giovanni de Simone, Lars H Lindholm, Hans Ibsen, Markku S. Nieminen, Vittorio Palmieri, Kristian Wachtell, Ole Lederballe-Pedersen, Björn Dahlöf, Stevo Julius, Suzanne Oparil, F Fyhrquist, Per Omvik
Publikováno v:
Circulation. 111:1924-1931
Background— Obesity may independently increase the risk of adverse events in hypertension with target-organ damage. We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::337c5adcbec69084ade109e0e27ab272
https://doi.org/10.1161/01.cir.0000161799.91577.0a
https://doi.org/10.1161/01.cir.0000161799.91577.0a
Autor:
Aud Høieggen, Michael H. Alderman, Sverre E. Kjeldsen, Stevo Julius, Richard B. Devereux, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Krister Kristianson, Ole Lederballe-Pedersen, Lars H. Lindholm, Markku S. Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Cong Chen, Björn Dahlöf, null for the LIFE Study Group
Publikováno v:
Kidney International. 65:1041-1049
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.BackgroundThe Losartan Intervention For Endpoint reduction in hypertension (LIFE) study demonstrated the superiority of a losartan-based regimen over atenolol-based regimen fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be960c2781afa918452aa58bf42e09c
https://doi.org/10.1111/j.1523-1755.2004.00484.x
https://doi.org/10.1111/j.1523-1755.2004.00484.x
Autor:
Sverre E. Kjeldsen, Ulf de Faire, Steven M. Snapinn, Richard B. Devereux, Gareth Beevers, Suzanne Oparil, Katherine E. Harris, Markku S. Nieminen, Per Omvik, Gilbert W. Gleim, Stevo Julius, Ole Lederballe-Pedersen, Lars H Lindholm, Frej Fyhrquist, Björn Dahlöf, Jonathan M. Edelman, Krister Kristianson, Hans Ibsen
Publikováno v:
Seminars in Cerebrovascular Diseases and Stroke. 3:165-170
LIFE was a multinational cardiovascular event outcomes study that assigned 9,193 patients with hypertension and electrocardiographic evidence of left ventricular hypertrophy to randomized, double-blind treatment with a regimen based on either losatan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34115bb33aac4e276c2765d56c0f997c
https://doi.org/10.1053/j.scds.2003.00.028
https://doi.org/10.1053/j.scds.2003.00.028
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
Autor:
Kristian Wachtell, Richard B. Devereux, Steven M. Snapinn, Björn Dahlöf, Frej Fyhrquist, Per Omvik, Jonathan M. Edelman, Suzanne Oparil, Stevo Julius, Lars H Lindholm, Sverre E. Kjeldsen, Ole Lederballe-Pedersen, Peter Aurup, Krister Kristianson, Ulf de Faire, Markku S. Nieminen, Michael H. Olsen, Gareth Beevers, Knut Borch-Johnsen, Hans Ibsen, Hans Wedel
Publikováno v:
Lindholm, L H, Ibsen, H, Borch-Johansen, K, Olesen, M H, Wachtell, K, Dahlöf, B, Devereaux, R B, Beevers, G, de Faire, U, Fyhrquist, F, Julius, S, Kjeldsen, S, Kristianson, K, Lederballe-Pedersen, O, Nieminen, M S, Omvik, P, Oparil, S, Wedel, H, Aurup, P, Edelman, J M & Snapinn, S 2002, ' Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study ' J Hypertension, pp. 1879-1886 .
There has been uncertainty about the risk of new-onset diabetes in hypertensive individuals treated with different blood pressure-decreasing drugs.To study this risk in hypertensive individuals who were at risk of developing diabetes mellitus in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057ccf698a9f2a09d44d28245e867fb9
https://doi.org/10.1097/00004872-200209000-00035
https://doi.org/10.1097/00004872-200209000-00035